BCHE and early-onset autosomal dominant Alzheimer disease: The current pharmaceutical treatment options for Alzheimer disease are still limited to symptomatic interventions by cholinesterase inhibitors (ChEIs) and N-methyl-d-aspartate receptor (NMDA) antagonist memantine, which were both shown to improve functional and cognitive outcomes in a significant percentage of Alzheimer disease patients (Trinh et al., 2003; Howard et al., 2012; Zhu et al., 2013; Dou et al., 2018).